Information Provided By:
Fly News Breaks for November 5, 2019
VIR
Nov 5, 2019 | 06:26 EDT
Barclays analyst Gena Wang initiated coverage of Vir Biotechnology with an Overweight rating and $25 price target. The company has four technology platforms that could provide "distinct and synergistic" approaches to multiple infectious diseases, Wang tells investors in a research note. She believes its lead candidate VIR-2218 showed "initial encouraging data" and provides "potential as a backbone compound" for a functional cure in hepatitis B virus.
News For VIR From the Last 2 Days
There are no results for your query VIR